The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Amedisys' revenue will expand 0.5% and EPS will wither 64.2%.
The average estimate for revenue is $375.5 million. On the bottom line, the average EPS estimate is $0.24.
Last quarter, Amedisys logged revenue of $370.8 million. GAAP reported sales were 3.2% higher than the prior-year quarter's $359.3 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $0.22. GAAP EPS of $0.18 for Q1 were 66% lower than the prior-year quarter's $0.53 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 43.8%, 410 basis points worse than the prior-year quarter. Operating margin was 3.4%, 500 basis points worse than the prior-year quarter. Net margin was 1.5%, 280 basis points worse than the prior-year quarter.
The full year's average estimate for revenue is $1.50 billion. The average EPS estimate is $0.99.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 834 members out of 927 rating the stock outperform, and 93 members rating it underperform. Among 196 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 165 give Amedisys a green thumbs-up, and 31 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Amedisys is hold, with an average price target of $12.33.
Over the decades, small-cap stocks like Amedisys have provided market-beating returns, provided they're value-priced and have solid businesses. Read about a pair of companies with a lock on their markets in "Too Small to Fail: 2 Small Caps the Government Won't Let Go Broke." Click here for instant access to this free report.
- Add Amedisys to My Watchlist.